TPX2 and hepatocellular carcinoma: Meanwhile, another research showed that TPX2 depletion in HCC-infiltrating CD8 + T cells restricted the antitumor activity of CD8 + T cells and attenuated the efficacy with anti-PD-1 therapy [16].